Critical appraisal:Ahmed KA, Abuodeh YA, Echevarria MI, Arrington JA, Stallworth DG, Hogue C, et al 2016 2
From Cancer Guidelines Wiki
Risk of bias assessment: cohort study
Subject selection
"New technology" group
- Selected group
Comparison group
- Selected group
Comparability of groups on demographic characteristics and clinical features
- Not comparable and not adjusted for differences
Measurement of outcomes
Same method of measurement used across comparison groups
- Yes
Completeness of follow-up
Was follow-up complete and were all patients included in the analysis?
- Yes (follow-up >95%) or survival analysis using all patients
Overall risk of bias
| High risk of bias | Additional comments: Please replace this text and include any additional comments in regards to your risk of bias rating |
This appraisal has been completed.
- Article
- Ahmed KA, Abuodeh YA, Echevarria MI, Arrington JA, Stallworth DG, Hogue C, et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. Ann Oncol 2016 Dec;27(12):2288-2294 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27637745.
- Assigned to
- User:Tamsin.parrish
- Topic area
- Guidelines:Melanoma
- Clinical question
Section below only relevant for Cancer Council Project Officer